Literature DB >> 21047231

Using market-exclusivity incentives to promote pharmaceutical innovation.

Aaron S Kesselheim1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21047231     DOI： 10.1056/NEJMhle1002961

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals.

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Fakhredin A Sayed Tabatabaei; Huub Schellekens; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  [New drugs policy: safety and quality].

Authors:  Ester Amado Guirado; Laura Diego; Rosa Madridejos Mora
Journal:  Aten Primaria       Date:  2011-04-14       Impact factor: 1.137

Review 3.  An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.

Authors:  Aaron S Kesselheim
Journal:  Milbank Q       Date:  2011-09       Impact factor: 4.911

4.  Patents or patients: who loses?

Authors:  Joanna Brougher; Konstantin M Linnik
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

5.  ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.

Authors:  Maryann Mazer-Amirshahi; Andrew Stolbach; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2017-11-28

6.  Correction to: ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.

Authors:  Maryann Mazer-Amirshahi; Andrew Stolbach; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2018-06

7.  Enhancing prescription drug innovation and adoption.

Authors:  G Caleb Alexander; Alec B O'Connor; Randall S Stafford
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

8.  Value-based pricing: incentive for innovation or zero net benefit?

Authors:  Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

Review 9.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

10.  How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012.

Authors:  Derek J Ward; Angharad Slade; Tracey Genus; Orsolina I Martino; Andrew J Stevens
Journal:  BMJ Open       Date:  2014-10-24       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.